Christopher Ryan Sullivan, Chief Financial Officer at Avalo Therapeutics, Inc. (AVTX), sold 47,000 shares at $18.55 ($949K) on 2026-05-06, disclosed to the SEC on 2026-05-07.
Scheduled sale ($949k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.55 | 13,834 | $257K | 27.1% |
| 2 | $19.28 | 12,347 | $238K | 25.1% |
| 3 | $20.76 | 2,700 | $56K | 5.9% |
| 4 | $21.37 | 9,219 | $197K | 20.8% |
| 5 | $22.57 | 8,900 | $201K | 21.2% |
| Total | $20.19 avg | 47,000 |
| $949K |
| 100% |
| Filing → |
| AVTX | SELL | 2026-08-19 | $1.5M | — | Filing → |
| AVTX | SELL | 2026-05-11 | $449K | — | Filing → |
| AVTX | SELL | 2026-05-01 | $223K | — | Filing → |